 |
12 Diseases |  |
138 Trials |
|
138 Trials |  |
3994 News |  |
| «12345678910111213...3940» |
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Atypical Presentation of Immune-mediated Myopathy () - Nov 16, 2023 - Abstract #AAPMR2023AAPMR_496;
This patient's case of nearly missed immune-mediated myopathy stresses the importance of thorough musculoskeletal and neurological assessments during emergency triage. Early recognition of such presentations of myopathies is imperative to early medical and rehabilitative treatment.
- ||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, cagrilintide (AM833) / Novo Nordisk, cagrilintide/semaglutide (CagriSema) / Novo Nordisk
New P2 trial: A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo (clinicaltrials.gov) - Nov 14, 2023
P2, N=618, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, cagrilintide (AM833) / Novo Nordisk, cagrilintide/semaglutide (CagriSema) / Novo Nordisk
New P3 trial, Combination therapy: A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight (clinicaltrials.gov) - Nov 14, 2023
P3, N=800, Not yet recruiting, Sponsor: Novo Nordisk A/S
- || bimagrumab (BYM338) / Novartis, Eli Lilly
Trial primary completion date: Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese (clinicaltrials.gov) - Nov 13, 2023
P2, N=507, Active, not recruiting, Sponsor: Eli Lilly and Company
Early recognition of such presentations of myopathies is imperative to early medical and rehabilitative treatment. Trial primary completion date: Sep 2025 --> May 2024
- || lotiglipron (PF-07081532) / Pfizer
Trial completion: A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range (clinicaltrials.gov) - Nov 13, 2023
P1, N=32, Completed, Sponsor: Pfizer
Trial primary completion date: Sep 2025 --> May 2024 Active, not recruiting --> Completed
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal, HEOR: Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial. (Pubmed Central) - Nov 12, 2023
In patients with HFpEF and obesity, semaglutide produced large improvements in HF-related symptoms, physical limitations, exercise function, inflammation, body weight and NTproBNP regardless of baseline health status. Benefits of semaglutide extended to all key KCCQ domains.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. (Pubmed Central) - Nov 12, 2023
P3
In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
- efruxifermin (AKR-001) / Amgen
SAFETY AND EFFICACY OF EFRUXIFERMIN IN COMBINATION WITH A GLP-1 RECEPTOR AGONIST (GLP-1RA) IN PATIENTS WITH NASH/MASH AND T2D: A RANDOMIZED, PLACEBO-CONTROLLED STUDY (COHORT D) () - Nov 11, 2023 - Abstract #AASLD2023AASLD_2859;
EFX provided clear benefits over GLP-1RA alone, normalizing LFC in most patients and further reducing markers of liver injury and fibrosis, while improving overall metabolic health through its action as an insulin sensitizer. The combination offers potential to accelerate resolution of steatohepatitis and reversal of fibrosis among the many patients with NASH and T2D.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment closed, Trial completion date, Trial primary completion date, Surgery, Bariatric surgery: BARI-STEP: Semaglutide 2.4 mg in Patients With Poor Weight-loss (clinicaltrials.gov) - Nov 7, 2023
P3, N=70, Active, not recruiting, Sponsor: University College, London
The combination offers potential to accelerate resolution of steatohepatitis and reversal of fibrosis among the many patients with NASH and T2D. Recruiting --> Active, not recruiting | Trial completion date: May 2024 --> Sep 2025 | Trial primary completion date: Mar 2024 --> Sep 2025
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Neutrophilic Urticaria Following Semaglutide Use () - Nov 6, 2023 - Abstract #ISDS2023ISDS_408;
We present a unique case of a patient with no significant medical history who recently started Semaglutide (Ozempic) for weight loss and developed a debilitating diffuse urticarial rash, requiring multiple emergency room visits for intramuscular epinephrine treatments...The patient discontinued Semaglutide and her symptoms significantly improved, but she continues to have breakthrough episodes of pruritic rash and edema, requiring self-treatment with Diphenhydramine...However, there have been multiple adverse outcomes reported with the use of Semaglutide, thus it is important to continue monitoring patients regardless of past medical history. With increasing fame and wide acceptance of these novel therapeutics, it is important to report such adverse outcomes to expand on ourliterature and understanding, to better educate our patient populations prior to the initiation of such therapies and provide a cautionary plan in the case that adverse events do occur
- || Mounjaro (tirzepatide) / Eli Lilly
Clinical, Retrospective data, Review: Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. (Pubmed Central) - Nov 4, 2023
With increasing fame and wide acceptance of these novel therapeutics, it is important to report such adverse outcomes to expand on ourliterature and understanding, to better educate our patient populations prior to the initiation of such therapies and provide a cautionary plan in the case that adverse events do occur When compared to all control groups consisting of basal insulin (glargine or degludec), selective GLP1-RA (dulaglutide or semaglutide once weekly), and placebo, an increased risk of pancreatitis was not found to be significantly associated with tirzepatide (RR 1.46, [95% CI] 0.59 to 3.61; I2
- | Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Implications of Ozempic (Pubmed Central) - Nov 3, 2023
Discontinuation of Ozempic should be considered prior to general anesthesia due to gastrointestinal side effects including delayed gastric emptying. As the popularity of Ozempic grows, facial plastic surgeons must be aware of both the impact on facial appearance and perioperative considerations.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment change, Trial withdrawal: SOCRATES-AF: Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients (clinicaltrials.gov) - Nov 3, 2023
P3, N=0, Withdrawn, Sponsor: Axel Brandes
As the popularity of Ozempic grows, facial plastic surgeons must be aware of both the impact on facial appearance and perioperative considerations. N=100 --> 0 | Not yet recruiting --> Withdrawn
- Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Whole-brain quantification of semaglutide-induced neuronal activation: a study of mRNA and protein signatures in mouse brains using light sheet fluorescence microscopy (WCC Halls A-C) - Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_12349;
N=100 --> 0 | Not yet recruiting --> Withdrawn In the present study, we characterized CNS stimulatory effects of semaglutide, currently approved for treatment of diabetes (Ozempic
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Review, Journal, Surgery, Bariatric surgery: What Is Best for Weight Loss? A Comparative Review of the Safety and Efficacy of Bariatric Surgery Versus Glucagon-Like Peptide-1 Analogue. (Pubmed Central) - Oct 31, 2023
However, semaglutide represents a valuable noninvasive alternative, offering significant weight reduction and lower risks of adverse effects. The choice between these interventions should be based on individual patient characteristics and a comprehensive assessment of the risk-benefit profile.
- ||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion: STEP HFpEF DM: Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes (clinicaltrials.gov) - Oct 31, 2023
P3, N=610, Completed, Sponsor: Novo Nordisk A/S
The choice between these interventions should be based on individual patient characteristics and a comprehensive assessment of the risk-benefit profile. Recruiting --> Completed
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, cagrilintide (AM833) / Novo Nordisk, cagrilintide/semaglutide (CagriSema) / Novo Nordisk
Trial primary completion date, Combination therapy: REDEFINE 1: A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight (clinicaltrials.gov) - Oct 30, 2023
P3, N=3400, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Completed Trial primary completion date: Jan 2025 --> Oct 2024
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical, Retrospective data, Review, Journal: Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis. (Pubmed Central) - Oct 28, 2023
Nevertheless, semaglutide was associated with increased incidence of gastrointestinal-related disorders. Further large, multicenter randomized controlled clinical trials are still needed to obtain more robust evidence to better guide clinical treatment decisions.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Effects of aerobic training and semaglutide treatment on pancreatic ?-cell secretory function in patients with type 2 diabetes. (Pubmed Central) - Oct 22, 2023
P=N/A
The combination of aerobic training and semaglutide treatment synergistically improved ?-cell secretory function. (ClinicalTrials.gov number, ID NCT04383197).
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial initiation date, Metastases: Feasibility of Semaglutide in Advanced Lung Disease (clinicaltrials.gov) - Oct 18, 2023
P1/2, N=8, Not yet recruiting, Sponsor: University of Pennsylvania
(ClinicalTrials.gov number, ID NCT04383197). Initiation date: Sep 2023 --> Dec 2023
- |||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, cagrilintide (AM833) / Novo Nordisk, cagrilintide/semaglutide (CagriSema) / Novo Nordisk
Enrollment open: REIMAGINE 2: A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor (clinicaltrials.gov) - Oct 17, 2023
P3, N=2700, Recruiting, Sponsor: Novo Nordisk A/S
Initiation date: Sep 2023 --> Dec 2023 Not yet recruiting --> Recruiting
- ||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, cagrilintide (AM833) / Novo Nordisk, cagrilintide/semaglutide (CagriSema) / Novo Nordisk
Enrollment change, Combination therapy: REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels (clinicaltrials.gov) - Oct 17, 2023
P3, N=7000, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting N=4000 --> 7000
- | New trial: Steno1: Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes (clinicaltrials.gov) - Oct 13, 2023
P=N/A, N=2000, Not yet recruiting, Sponsor: Steno Diabetes Center Copenhagen
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial primary completion date: Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication? (clinicaltrials.gov) - Oct 10, 2023
P4, N=104, Recruiting, Sponsor: Anders Fink-Jensen, MD, DMSci
N=4000 --> 7000 Trial primary completion date: Sep 2024 --> Jul 2024
- | Saxenda (liraglutide 3 mg) / Novo Nordisk
Enrollment open, Trial completion date, Inflammatory cell: Anti-obesity Pharmacotherapy and Inflammation (clinicaltrials.gov) - Oct 4, 2023
P=N/A, N=24, Recruiting, Sponsor: Louisiana State University Health Sciences Center in New Orleans
Trial primary completion date: Sep 2024 --> Jul 2024 Not yet recruiting --> Recruiting | Trial completion date: Jan 2024 --> Apr 2024
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, cagrilintide (AM833) / Novo Nordisk, cagrilintide/semaglutide (CagriSema) / Novo Nordisk
New P3 trial: REIMAGINE 2: A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor (clinicaltrials.gov) - Oct 3, 2023
P3, N=2700, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
Journal: Glucose-lowering effects of semaglutide compared with dulaglutide using professional continuous glucose monitoring in outpatients with type 2 diabetes mellitus: a pilot study. (Pubmed Central) - Oct 2, 2023
The results suggest that switching to SG may be a useful option in patients experiencing inadequate glycemic control with DG. The online version contains supplementary material available at 10.1007/s13340-023-00640-2.
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Awiqli (insulin icodec) / Novo Nordisk
Enrollment open, Trial completion date: A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes (clinicaltrials.gov) - Oct 2, 2023
P3, N=148, Recruiting, Sponsor: Novo Nordisk A/S
The online version contains supplementary material available at 10.1007/s13340-023-00640-2. Not yet recruiting --> Recruiting | Trial completion date: Mar 2025 --> Jul 2025
- ||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion date, Trial primary completion date: SMART: SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes (clinicaltrials.gov) - Sep 30, 2023
P3, N=98, Enrolling by invitation, Sponsor: University Medical Center Groningen
Not yet recruiting --> Recruiting | Trial completion date: Mar 2025 --> Jul 2025 Trial completion date: May 2023 --> Oct 2024 | Trial primary completion date: May 2023 --> Mar 2024
- ||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion: A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes (clinicaltrials.gov) - Sep 30, 2023
P3, N=401, Completed, Sponsor: Novo Nordisk A/S
Trial completion date: May 2023 --> Oct 2024 | Trial primary completion date: May 2023 --> Mar 2024 Recruiting --> Completed
- | Tresiba (insulin degludec) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P1/2 trial: Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus (clinicaltrials.gov) - Sep 28, 2023
P1/2, N=120, Not yet recruiting, Sponsor: Ministry of Health, Saudi Arabia
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial initiation date: Semaglutide Therapy for Alcohol Reduction (STAR) (clinicaltrials.gov) - Sep 27, 2023
P2, N=52, Recruiting, Sponsor: National Institute on Drug Abuse (NIDA)
Recruiting --> Completed Initiation date: Sep 2023 --> Dec 2023
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, cagrilintide (AM833) / Novo Nordisk, cagrilintide/semaglutide (CagriSema) / Novo Nordisk
Trial completion date, Trial primary completion date, Combination therapy: REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels (clinicaltrials.gov) - Sep 26, 2023
P3, N=4000, Recruiting, Sponsor: Novo Nordisk A/S
Initiation date: Sep 2023 --> Dec 2023 Trial completion date: May 2027 --> Oct 2027 | Trial primary completion date: May 2027 --> Sep 2027
- |||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: STEP12: A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range (clinicaltrials.gov) - Sep 21, 2023
P3, N=162, Recruiting, Sponsor: Novo Nordisk A/S
Trial completion date: May 2027 --> Oct 2027 | Trial primary completion date: May 2027 --> Sep 2027 Not yet recruiting --> Recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion: Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) (clinicaltrials.gov) - Sep 21, 2023
P2, N=51, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P3 trial: STEP12: A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range (clinicaltrials.gov) - Sep 18, 2023
P3, N=162, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: SERENA: Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes (clinicaltrials.gov) - Sep 18, 2023
P3, N=252, Recruiting, Sponsor: Universitaire Ziekenhuizen KU Leuven
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Enrollment open: OTID: Obesity Treatment to Improve Diabetes (clinicaltrials.gov) - Sep 18, 2023
P=N/A, N=60, Recruiting, Sponsor: Dasman Diabetes Institute
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || metformin / Generic mfg.
Review, Journal: Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review. (Pubmed Central) - Sep 17, 2023
The 10 GLP-1RAs are exenatide (including exenatide twice daily and once weekly), liraglutide, lixisenatide, dulaglutide, PEX168, semaglutide (subcutaneous and oral semaglutide), tirzepatide and albiglutide...In addition, this study may provide reference and evidence-based medical evidence for clinicians to select GLP-1RAs in patients with T2D and high body mass index (BMI). Based on the NMA results, tirzepatide 15mg and semaglutide 1.0mg may be preferred.
- || Review, Journal: A narrative review of approved and emerging anti-obesity medications. (Pubmed Central) - Sep 15, 2023
The use of AOM increased enormously despite its sometimes-dubious safety and ineffectiveness. The public and medical professionals should be vigilant to the real-world benefits of anti-obesity drugs and their achieved effectiveness with an improved safety profile.
- ||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion: Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis (clinicaltrials.gov) - Sep 14, 2023
P3, N=407, Completed, Sponsor: Novo Nordisk A/S
The public and medical professionals should be vigilant to the real-world benefits of anti-obesity drugs and their achieved effectiveness with an improved safety profile. Active, not recruiting --> Completed
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
New P2 trial: Can Semaglutide or empagliflozin stabilise coronary atherosclerosis in people with type 2 diabetes after acute coronary syndrome (EUDRACT) - Sep 13, 2023
P2, N=132, Not yet recruiting, Sponsor: South Australian Health and Medical Research Institute
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Enrollment open: Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (clinicaltrials.gov) - Sep 13, 2023
P2, N=60, Recruiting, Sponsor: Yale University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Saxenda (liraglutide 3 mg) / Novo Nordisk
Observational data, Journal: Knowledge and Attitude of the General Population in Saudi Arabia Toward Weight Management Medications (WMMs): A Cross-Sectional Study. (Pubmed Central) - Sep 7, 2023
- |||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, cagrilintide (AM833) / Novo Nordisk, cagrilintide/semaglutide (CagriSema) / Novo Nordisk
Enrollment open, Combination therapy: REDEFINE 6: A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight (clinicaltrials.gov) - Sep 6, 2023
P3, N=300, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
New P2 trial: Semaglutide Therapy for Alcohol Reduction (STAR) (clinicaltrials.gov) - Aug 29, 2023
P2, N=52, Recruiting, Sponsor: National Institute on Drug Abuse (NIDA)
- || Ozempic (semaglutide SC once-weekly) / Novo Nordisk, cagrilintide (AM833) / Novo Nordisk
P2 data, Journal: Efficacy and safety of co-administered once-weekly cagrilintide 2 (Pubmed Central) - Aug 28, 2023
P2
Treatment with CagriSema resulted in significantly greater weight loss versus semaglutide and cagrilintide and was well tolerated. These data support further investigation of CagriSema in this population in longer and larger phase 3 studies.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity. (Pubmed Central) - Aug 26, 2023
These data support further investigation of CagriSema in this population in longer and larger phase 3 studies. Cardiometabolic Disease Staging risk assessment suggests that once-weekly semaglutide 2.4 mg may substantially lower 10-year T2D risk in people with overweight or obesity.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis. (Pubmed Central) - Aug 26, 2023
This was a subanalysis of the SWITCH-SEMA 1 study, a multicenter, prospective, randomized, parallel-group trial comparing switching from liraglutide or dulaglutide to once-weekly semaglutide in subjects with T2DM (SWITCH) versus continuing current GLP-1RAs (Continue) for 24 weeks...The multiple linear regression analysis revealed that the switch from dulaglutide was associated with an improvement in FLI (p = 0.041). Switching from conventional GLP-1RAs to once-weekly semaglutide might be beneficial for individuals with NAFLD complicated with T2DM.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. (Pubmed Central) - Aug 25, 2023
P3
In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo. (Funded by Novo Nordisk; STEP-HFpEF ClinicalTrials.gov number, NCT04788511.).